A Phase 1, Dose Escalation Study of Plerixafor in Combination With Induction and Consolidation Chemotherapy in Patients With Relapsed Acute Myeloid Leukemia.

Trial Profile

A Phase 1, Dose Escalation Study of Plerixafor in Combination With Induction and Consolidation Chemotherapy in Patients With Relapsed Acute Myeloid Leukemia.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 19 Mar 2016

At a glance

  • Drugs Plerixafor (Primary) ; Cytarabine; Daunorubicin; Granulocyte colony-stimulating factors
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Acronyms PRIMAL
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Aug 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 03 Oct 2014 Planned End Date changed from 1 Dec 2013 to 1 Mar 2015 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top